CEO John Marotta since September 2024 has executed a turnaround at Azenta by divesting B Medical, simplifying IT and legal structures, and cutting roughly 380 roles to shift spend from G&A into R&D and sales; monthly KPIs now track quality, delivery, margin, free cash flow and return on invested capital.

Kaizen projects have delivered step-change results, reducing GENEWIZ delivery times from 25 days to nine hours, clearing sample registration backlogs from weeks to days, cutting store complaints by 55%, and raising on-time delivery from about 15% to 65%.

Azenta reported $600 million in annual revenue, manages 60 million samples worldwide and supports over 1 billion samples through customer sites and biorepositories, while holding $550 million in cash for margin improvements, growth investments, M&A and buybacks within a $6 billion serviceable addressable market at roughly 10% penetration.

The company’s two core segments include Sample Management Solutions with nine global repositories and automated ultra-low temperature storage, and Multiomics with 14 sequencing labs and a profitable gene synthesis unit, all supported by a digital ordering ecosystem and ongoing commercial reboots in Europe and North America.